Autolus Therapeutics (NASDAQ:AUTL – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm currently has a $3.00 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 7.14% from the company’s current price. […]
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric.
Wall Street analysts expect Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) to report $260,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Autolus Therapeutics’ earnings, with the lowest sales estimate coming in at $220,000.00 and the highest estimate coming in at $300,000.00. Autolus Therapeutics posted sales of […]
Shares of Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) have been assigned an average recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price […]
Wall Street analysts forecast that Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) will report earnings of ($0.51) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Autolus Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.61). Autolus Therapeutics posted […]